- Home
- AGEN vs AISP Comparison
AGEN vs AISP Comparison
Compare AGEN & AISP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- AISP
- Stock Information
- Founded
- AGEN 1994
- AISP 2006
- Country
- AGEN United States
- AISP United States
- Employees
- AGEN N/A
- AISP N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- AISP Blank Checks
- Sector
- AGEN Health Care
- AISP Finance
- Exchange
- AGEN Nasdaq
- AISP Nasdaq
- Market Cap
- AGEN 142.8M
- AISP 166.9M
- IPO Year
- AGEN 2000
- AISP N/A
- Fundamental
- Price
- AGEN $4.55
- AISP $5.67
- Analyst Decision
- AGEN Buy
- AISP Strong Buy
- Analyst Count
- AGEN 2
- AISP 1
- Target Price
- AGEN $14.50
- AISP $6.00
- AVG Volume (30 Days)
- AGEN 395.5K
- AISP 789.4K
- Earning Date
- AGEN 11-11-2025
- AISP 11-13-2025
- Dividend Yield
- AGEN N/A
- AISP N/A
- EPS Growth
- AGEN N/A
- AISP N/A
- EPS
- AGEN N/A
- AISP N/A
- Revenue
- AGEN $101,706,000.00
- AISP $13,724,085.00
- Revenue This Year
- AGEN $60.49
- AISP $34.52
- Revenue Next Year
- AGEN N/A
- AISP $59.54
- P/E Ratio
- AGEN N/A
- AISP N/A
- Revenue Growth
- AGEN N/A
- AISP N/A
- 52 Week Low
- AGEN $1.38
- AISP $1.90
- 52 Week High
- AGEN $7.34
- AISP $7.66
- Technical
- Relative Strength Index (RSI)
- AGEN 48.05
- AISP 66.25
- Support Level
- AGEN $4.36
- AISP $4.17
- Resistance Level
- AGEN $5.20
- AISP $5.55
- Average True Range (ATR)
- AGEN 0.27
- AISP 0.28
- MACD
- AGEN 0.04
- AISP 0.15
- Stochastic Oscillator
- AGEN 40.91
- AISP 94.34
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About AISP Airship AI Holdings Inc.
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.